Professor Eric Morand |
Improved outcomes for patients with lupus
are expected as a result of research funding worth nearly $.75 million, secured
by researchers in the School of
Clinical Sciences at Monash Health (SCS).
Pharmaceutical companies UCB Biopharma
SPRL and GlaxoSmithKline
(GSK), who are among
the leading companies worldwide developing therapies for lupus, are to fund
research led by Professor
Eric Morand, Head of SCS and
Head of Rheumatology at Monash Health, to develop and validate treatment
targets in lupus.
“Systemic
lupus erythematosus (SLE, or lupus)
is a serious multisystem autoimmune disease,” said Professor Morand. “Patients
with lupus, usually young women, suffer a loss of life expectancy and in some
cases severe illness, caused by the immune system damaging multiple organs.”